JPH0369890B2 - - Google Patents

Info

Publication number
JPH0369890B2
JPH0369890B2 JP58035200A JP3520083A JPH0369890B2 JP H0369890 B2 JPH0369890 B2 JP H0369890B2 JP 58035200 A JP58035200 A JP 58035200A JP 3520083 A JP3520083 A JP 3520083A JP H0369890 B2 JPH0369890 B2 JP H0369890B2
Authority
JP
Japan
Prior art keywords
therapeutic agent
depression
disease
represent
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58035200A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5925323A (ja
Inventor
Kuruteiusu Hansuukurisutofu
Myurudonaa Hainritsuhiigeorugu
Niidaabiizeru Aaroisu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanegafuchi Chemical Industry Co Ltd
Original Assignee
Kanegafuchi Chemical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanegafuchi Chemical Industry Co Ltd filed Critical Kanegafuchi Chemical Industry Co Ltd
Publication of JPS5925323A publication Critical patent/JPS5925323A/ja
Publication of JPH0369890B2 publication Critical patent/JPH0369890B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP58035200A 1982-03-03 1983-03-02 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 Granted JPS5925323A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH130082 1982-03-03
CH1300/82 1982-03-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2052418A Division JPH02262517A (ja) 1982-03-03 1990-03-02 プテリン誘導体からなる精神疾患症状の治療剤
JP4257964A Division JPH05194229A (ja) 1982-03-03 1992-09-28 プテリン誘導体からなる精神疾患症状の治療剤

Publications (2)

Publication Number Publication Date
JPS5925323A JPS5925323A (ja) 1984-02-09
JPH0369890B2 true JPH0369890B2 (enExample) 1991-11-05

Family

ID=4207209

Family Applications (3)

Application Number Title Priority Date Filing Date
JP58035200A Granted JPS5925323A (ja) 1982-03-03 1983-03-02 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
JP2052418A Pending JPH02262517A (ja) 1982-03-03 1990-03-02 プテリン誘導体からなる精神疾患症状の治療剤
JP4257964A Pending JPH05194229A (ja) 1982-03-03 1992-09-28 プテリン誘導体からなる精神疾患症状の治療剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2052418A Pending JPH02262517A (ja) 1982-03-03 1990-03-02 プテリン誘導体からなる精神疾患症状の治療剤
JP4257964A Pending JPH05194229A (ja) 1982-03-03 1992-09-28 プテリン誘導体からなる精神疾患症状の治療剤

Country Status (2)

Country Link
US (2) US4758571A (enExample)
JP (3) JPS5925323A (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
EP0318926B1 (en) * 1987-11-30 1995-05-03 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives
US6172039B1 (en) 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
US5534514A (en) * 1992-10-27 1996-07-09 San Diego State University Anti-neoplastic compositions and methods for application thereof
DE69526918T2 (de) * 1994-08-05 2002-12-19 Suntory Ltd., Osaka Arzneimittel gegen spinocerebellare degeneration
DE69725721T3 (de) 1996-08-30 2007-10-31 Daiichi Asubio Pharma Co., Ltd. Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind
JP4842415B2 (ja) * 1996-08-30 2011-12-21 第一三共株式会社 Ｎｏｓの機能低下が寄与する疾患の予防または治療剤
JP4306825B2 (ja) 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
ES2242381T3 (es) * 1998-02-27 2005-11-01 Daiichi Suntory Pharma Co., Ltd. Agentes profilacticos o remedios contra los trastornos renales de origen medicamentoso.
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6319905B1 (en) * 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US20060110325A1 (en) * 2003-02-21 2006-05-25 Hinz Martin C Serotonin and catecholamine segment optimization technology
US20030181509A1 (en) * 2002-03-21 2003-09-25 Hinz Martin C. Serotonin and catecholamine system segment optimization technology
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US6830281B2 (en) * 2002-09-20 2004-12-14 Lawrence Andrew Hoffman Power tonneau cover actuator
DE10260263A1 (de) * 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
EP1603448A4 (en) * 2003-02-21 2007-12-05 Martin C Hinz SEROTONIN AND CATECHOLAMINE SYSTEM SEGMENT OPTIMIZATION TECHNOLOGY
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2545584C (en) 2003-11-17 2012-10-23 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of metabolic disorders
JP2007536210A (ja) 2003-11-17 2007-12-13 メルック・エプロバ・アクチエンゲゼルシヤフト （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
WO2006004719A2 (en) * 2004-06-25 2006-01-12 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
AU2005306686B2 (en) 2004-11-17 2011-06-02 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
US20100130500A1 (en) * 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
AU2006321942A1 (en) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
US8017348B1 (en) 2005-12-12 2011-09-13 Elan Pharma International Limited Assay for Parkinson's Disease therapeutics
US20090317825A1 (en) * 2005-12-12 2009-12-24 Elan Pharma International Limited Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
JPWO2007119367A1 (ja) * 2006-03-20 2009-08-27 株式会社カネカ ビオプテリンを含む組成物及びその使用方法
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
DK2139485T3 (da) 2007-04-11 2013-01-21 Biomarin Pharm Inc Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
MX2010006025A (es) * 2008-01-03 2010-06-30 Biomarin Pharm Inc Analogo de pterina para tratar afeccion sensible a bh4.
KR20120022849A (ko) * 2009-04-09 2012-03-12 베일러 리서치 인스티튜트 파브리병을 위한 마커 및 치료제로서의 테트라하이드로바이오프테린의 용도
JP5066756B2 (ja) * 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP3548487A4 (en) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. POLYMORPHE SHAPE OF SEPIAPTERIN
IL301470A (en) * 2016-11-29 2023-05-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
CA3073957A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Pharmaceutical compositions comprising sepiapterin and uses thereof
RS65874B1 (sr) 2018-05-30 2024-09-30 Ptc Therapeutics Mp Inc Primena sepiapterina bez hrane za upotrebu u postupku za povećanje izloženosti plazme sepiapterinu
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
JPH0692302B2 (ja) * 1986-09-02 1994-11-16 鐘淵化学工業株式会社 神経病治療剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIE PARKINSON-KRANKHEIT=1980 *

Also Published As

Publication number Publication date
US4758571A (en) 1988-07-19
JPH05194229A (ja) 1993-08-03
JPS5925323A (ja) 1984-02-09
JPH02262517A (ja) 1990-10-25
US4774244A (en) 1988-09-27

Similar Documents

Publication Publication Date Title
JPH0369890B2 (enExample)
EP0209689B1 (en) Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism
EP0898965B9 (de) Verwendung von 5-methyl-(6S)-tetrahydrofolsäure zur Vorbeugung von Neuralrohrdefekten
JP3221880B2 (ja) 抗うつ作用を有する医薬組成物としての２‐アミノ‐６‐ｎ‐プロピル‐アミノ‐４，５，６，７‐テトラヒドロベンゾチアゾールの使用
JP2010511603A (ja) メタドキシンとニンニク油を含有するアルコール性脂肪肝並びに脂肪肝性肝炎の予防及び治療用薬学組成物
EP1969117A2 (en) A method to treat premature ejaculation in humans
JPH0733332B2 (ja) 痴呆症状改善・治療剤
EP0983765B1 (en) Preventives or remedies for diseases in association with vascular functional anomaly relating to insulin resistance
ME02149B (me) FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE
US5011841A (en) Treatment of depression
US20160000716A1 (en) Method of treating vitamin b12 deficiency
SK92099A3 (en) Use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole, its (-)-enantiomer and its pharmacologically acceptable salts for the preparation of a medicament in treatment of restless legs syndrome
EP1210089A2 (en) Oral combinations of hydroxocobalamin and folic acid
EP1835917B1 (de) Mittel, enthaltend folsäure, vitamin b6 und vitamin b12, und dessen verwendung
JPH06305962A (ja) アトピー性皮膚炎治療剤
JPH0415767B2 (enExample)
JP2845988B2 (ja) ベンフォチアミン製剤
Toothaker Enoxacin absorption and elimination characteristics
JPWO2021062264A5 (enExample)
JP6940109B2 (ja) 認知症における認知機能改善用組成物
BE829197A (fr) Compositions anti-inflammatoires, leur preparation et leur utilisation
Pilotto et al. The effect of omeprazole on serum concentrations of theophylline, pepsinogens A and C, and gastrin in elderly duodenal ulcer patients
JP2002104961A (ja) 悪酔い及び二日酔いの予防・改善効果を有する食品及び医薬品
Tester-Dalderup Antihistamines
JPH06305963A (ja) 疲労改善剤